John F. Gerecitano

Memorial Sloan Kettering Cancer Center — United States

Medicine · Health Sciences

38h-index10.5kcitations204works2.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(105), Chronic Lymphocytic Leukemia Research(90), Chronic Myeloid Leukemia Treatments(21), Viral-associated cancers and disorders(18), Acute Lymphoblastic Leukemia research(16)

Publications204 total

<i>Erratum</i> to: Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation
Haematologica·2024· 2 citedOpen Access
Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation
Haematologica·2023· 4 citedOpen Access
P624: PHASE 1 STUDY OF JNJ-67856633, A FIRST-IN-HUMAN HIGHLY SELECTIVE MALT1 INHIBITOR, IN RELAPSED/REFRACTORY (R/R) B-CELL NON-HODGKIN LYMPHOMA (B-NHL) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
HemaSphere·2023· 1 citedOpen Access
PHASE 1 STUDY OF JNJ‐67856633, A FIRST‐IN‐HUMAN MALT1 INHIBITOR, IN RELAPSED/REFRACTORY (<i>R</i>/<i>R</i>) B‐CELL NON‐HODGKIN LYMPHOMA (B‐NHL) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
Hematological Oncology·2023· 5 citedOpen Access
Supplementary Figures from Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer
2023Open Access
Supplementary Material and Method from Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer
2023Open Access
Data from The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma
2023Open Access
Supplementary Figures 1-3 from A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas
2023Open Access
Supplemental Figure 2 from Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring
2023Open Access
Supplementary Data from Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring
2023Open Access
Supplementary Tables from Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer
2023Open Access
Data from Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring
2023Open Access
Data from Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
2023Open Access
Supplemental Figure 3 from Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring
2023Open Access
Supplementary Figure S1 from The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma
2023Open Access
Supplementary Figure Legend from Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer
2023Open Access
Supplementary Figures 1-3 from A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas
2023Open Access
Supplementary Data from Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
2023Open Access
Supplementary Data from Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring
2023Open Access
Supplemental Figure 1 from Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring
2023Open Access
page 1 of 11Next →

Frequent Co-authors

Andrew D. Zelenetz(14), Paul A. Hamlin(13), Craig H. Moskowitz(12), Matthew J. Matasar(12), Ariela Noy(12), David J. Straus(12), Anas Younes(11), Andrew W. Roberts(10), Matthew S. Davids(10), Rod Humerickhouse(10), Alison J. Moskowitz(10), Carol S. Portlock(10), John M. Pagel(9), Brad S. Kahl(9), Mary Ann Anderson(9), Lori A. Gressick(9), William G. Wierda(9), John F. Seymour(9), Steven M. Horwitz(9), Elisa Cerri(8)